C2N Diagnostics
St. Louis, US · Delaware LLC · 1 known investors
C2N Diagnostics develops and commercializes blood-based diagnostic tests for Alzheimer's disease and other neurodegenerative conditions, using proprietary LC-MS/MS mass spectrometry to detect brain amyloid pathology. Its PrecivityAD, PrecivityAD2, and Precivity-ApoE tests serve health care professionals evaluating patients with cognitive impairment, available across all 50 US states and the District of Columbia.
BiotechDigital HealthMedical Devices
Founders & leadership
DD
Dr. David HoltzmanCo-founder
DR
Dr. Randall BatemanCo-founder
DJ
Dr. Joel BraunsteinCo-founder
MO
Micah OnixtExecutive
Board
DM
Dr. Michael GoldblattBoard director
Investors · 1
Also in the syndicate · 1
Alzheimer's Drug Discovery Foundation
Reported raises · per SEC filings
Form D private placements$35M disclosed across 2 of 3 rounds · 2024–2026
▶$10MraisedMay 2025 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedMay 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fred MillerDirector
- Dr. Michael GoldblattDirector
- Micah OnixtExecutive Officer
- Dr. David HoltzmanDirector
- Dr. Randall BatemanDirector
- Dr. Joel BraunsteinExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- May 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$25MraisedSep 2024 · 3 investors · BiotechnologyRule 506(b)
▶$25MraisedSep 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. David HoltzmanDirector
- Dr. Randall BatemanDirector
- Micah OnixtExecutive Officer
- Dr. Joel BraunsteinExecutive Officer, Director
- Dr. Michael GoldblattDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapLabcorp35 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Quest Diagnostics26 shared keywordsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
Companies competing with C2N Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does C2N Diagnostics do?
- C2N Diagnostics develops and commercializes blood-based diagnostic tests for Alzheimer's disease and other neurodegenerative conditions, using proprietary LC-MS/MS mass spectrometry to detect brain amyloid pathology. Its PrecivityAD, PrecivityAD2, and Precivity-ApoE tests serve health care professionals evaluating patients with cognitive impairment, available across all 50 US states and the District of Columbia.
- Who founded C2N Diagnostics?
- C2N Diagnostics was founded by Dr. David Holtzman, Dr. Randall Bateman, Dr. Joel Braunstein.
- How much funding has C2N Diagnostics raised?
- C2N Diagnostics has disclosed $35M raised across 2 of its 3 known rounds.
- Where is C2N Diagnostics headquartered?
- C2N Diagnostics is headquartered in St. Louis, US.